Humana External Revenues
External Revenues at Humana came to $40.8B for the quarter to 30 Sep 2026, up 26.4% from a year earlier.
As Humana reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 6 Nov 2026.
By quarter
| Period ending | External Revenues | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $40.8B | up 26.4% | 6 Nov 2026 |
| 30 Jun 2026 | $40.6B | up 26.5% | 29 Jul 2026 |
| 31 Mar 2026 | $39.4B | up 23.7% | 29 Apr 2026 |
| 31 Dec 2025 | $32.4B | up 12.0% | 19 Feb 2026 |
| 30 Sep 2025 | $32.3B | up 11.2% | 5 Nov 2025 |
| 30 Jun 2025 | $32.1B | up 9.8% | 30 Jul 2025 |
| 31 Mar 2025 | $31.8B | up 8.6% | 30 Apr 2025 |
| 31 Dec 2024 | $28.9B | up 10.5% | 20 Feb 2025 |
| 30 Sep 2024 | $29.1B | up 11.3% | 30 Oct 2024 |
| 30 Jun 2024 | $29.2B | up 10.5% | 31 Jul 2024 |
| 31 Mar 2024 | $29.3B | up 10.4% | 24 Apr 2024 |
| 31 Dec 2023 | $26.2B | — | 15 Feb 2024 |
| 30 Sep 2023 | $26.1B | up 15.4% | 1 Nov 2023 |
| 30 Jun 2023 | $26.5B | — | 2 Aug 2023 |
| 31 Mar 2023 | $26.5B | — | 26 Apr 2023 |
| 30 Sep 2022 | $22.6B | — | 2 Nov 2022 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Humana: Premiums and services revenue detail (State-based contracts and other · Insurance) · Home Solutions episodic admissions · PPO/PFFS individual medicare advantage membership · CenterWell, Pharmacy solutions premiums and services revenue detail · CenterWell, Primary care premiums and services revenue detail · CenterWell, Home solutions premiums and services revenue detail · CenterWell premiums and services revenue detail · Mail-Order penetration (Pharmacy Solutions, Total Medicare) · Services revenue · Insurance revenue · CenterWell revenue · financial statements
Every KPI and segment of HUM, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
